Predicting and preventing thromboembolic events in patients receiving cisplatin-based chemotherapy for germ cell tumours
Authors:
- 1 December 2016
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 69, 151-157
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Guidelines on Testicular Cancer: 2015 UpdateEuropean Urology, 2015
- Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancerAnnals of Oncology, 2012
- Observational Study of Prevalence of Long-term Raynaud-Like Phenomena and Neurological Side Effects in Testicular Cancer SurvivorsJNCI: Journal of the National Cancer Institute, 2009
- Medical Treatment of Advanced Testicular CancerJAMA, 2008
- Chemotherapy for Advanced Germ Cell TumorsJournal of Clinical Oncology, 2006
- Long-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular CancerJournal of Clinical Oncology, 2006
- Acute Chemotherapy-Induced Cardiovascular Changes in Patients With Testicular CancerJournal of Clinical Oncology, 2005
- The risk of thrombo-embolic events is increased in patients with germ-cell tumours and can be predicted by serum lactate dehydrogenase and body surface areaBritish Journal of Cancer, 2005
- Germ-cell tumor survivors: the price for cureAnnals of Oncology, 2002
- Thromboembolic Events During Chemotherapy for Germ Cell Cancer: A Cohort Study and Review of the LiteratureJournal of Clinical Oncology, 2000